|
200 Connell Dr. Berkeley Heights, NJ 07922 NJ Tel. 908-286-9800 Fax 908-464-1701 |
Type: Public
On the web:
http://www.genta.com
Employees:
25
Employee growth: (46.8%)
Genta plays rough with cancer. The firm develops drugs, including DNA/RNA medicines and more traditional small molecule drugs, for cancer and other diseases. Lead candidate Genasense blocks production of a protein that can cause resistance to cancer treatments. The company is hoping for marketing approval of Genasense to be used in conjunction with chemotherapy by patients with lymphocytic leukemia and malignant melanoma. Genasense is also in clinical trials for treatment of other diseases, such as prostate and colon cancer. Its small molecule program yielded Ganite, an FDA-approved treatment for hypercalcemia (a potentially fatal side effect of cancer); but the company does not actively market the drug.
Key numbers for fiscal year ending December, 2008:
Sales: $0.4M
One year growth: (37.4%)
Net income: ($505.8)M
Officers:
Chairman and CEO: Raymond P. Warrell Jr.
SVP and COO: W. Lloyd Sanders
VP Finance: Gary Siegel
Competitors:
Isis Pharmaceuticals
Lorus Therapeutics
NeoPharm
